buy AB-FUBINACA crystal
buy AB-FUBINACA crystal is a drug that acts as a potent agonist for the cannabinoid receptors, with values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2.I was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported.
⦁ SUBSTANCE IDENTIFICATION AND CHEMISTRY
AB-FUBINACA and AMB-FUBINACA are synthetic cannabinoids of the class of substituted indazole-3-carboxamides.
CAS Number: 1185282-01-2
Molecular weight: 368.4099 g/mol
Molecular formula: C20H21FN4O2
White crystalline solid.
AB-FUBINACA contains a chiral centre at the C-2 carbon of the 1-amino-3-methyl-1-oxobutan-2-yl side chain. This means that the substance also exists as the R-AB-FUBINACA enantiomer.
(ChemId, AMB-FUBINACA) ⦁ AMB-FUBINACA
⦁ N-[[1-[(4-fluorophenyl)methyl]-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester
⦁ AK-47 24 Carat Gold
⦁ Train Wreck2
⦁ methyl (2S)-2-[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3-methylbutanoate
CAS Number 1971007-92-7
Molecular weight: 383.4208 g/mol
Molecular formula: C21H22FN3O3
White to yellowish powder, slightly sweetish to the taste, with a sweet somewhat pleasant aroma.
AMB-FUBINACA contains a chiral centre at the C-2 carbon of the valinate sidechain. This means that the substance also exists as the R-AMB-FUBINACA enantiomer.
1A. Similarities to other substances
AB-FUBINACA is classified as an indazole. AB-FUBINACA is based on an indazole core structure where the 1- and 3-positions of the indazole ring system are substituted. The 1-position of AB-FUBINACA is substituted with a para-fluorobenzyl group. The 3-position is substituted with an amide linker, and the nitrogen atom (N) of this linker is further substituted with an acyclic alkyl amide, named 1-amino-3-methyl-1-oxobutan-2-yl.
AMB-FUBINACA is the methyl ester analogue of AB-FUBINACA, where the terminal amide group of the 1-amino-3-methyl-1-oxobutan-2-yl is replaced with a methyl ester group. It is reported to be 75-85 times more powerful at CB1 than THC, and 50 times more potent than JWH-018.
It was first reported in Louisiana in 2014, in a synthetic cannabis product called ‘Train Wreck 2’. It came to prominence in 2016, when there were a number of cases of “zombie-like” behaviour amongst users in New York City (The Drug Classroom, 2016; New York Times, December 2016; Bautista 2016; Adams et al, 2017). It was first reported in New Zealand in 2017 in association with similar occurrences (Stuff website, September 2017a).
Both substances are structurally related to AB-PINACA, ADB-PINACA, AB-CHMINACA, 5-fluoro AMP, and MDMB-FUBINACA, all of which are also synthetic cannabinoids.
2B. Background and history of use
AB-FUBINACA was marketed in New Zealand as a “legal” synthetic cannabis in the early 2010s. Interim product approvals were granted under the Psychoactive Substances Act 2013 until these were revoked on grounds that these posed more than a low risk of harm under Section 40 of that Act. AMB- FUBINACA does not appear to have been available in New Zealand prior to late 2016 or early 2017.
3C. Methods and ease of manufacturing
The synthesis of AB-FUBINACA is described in a 2009 patent by Pfizer Inc. on Indazole Derivatives, in which AMB-FUBINACA is a derivative. The patent is publicly accessible on the Google Patents website (Google.com).
The methods and ease of manufacturing synthetic cannabis can be found in the accompanying Synthetic Cannabinoids report prepared for the EACD.
⦁ RISK OF HARM
3a. Likelihood or Evidence of Abuse
While no deaths appear to be associated with AB-FUBINACA, there are reports of erratic behaviour and hospitalisations from use of the substance (Brenneman et al, 2016).
AMB-FUBINACA has been associated with a number of deaths which are currently the subject of a coronial investigation (Stuff website, September 2017a; New Zealand Police, September 2017).